Latest News

Learn how pharmacists vet financial planners: CFP credentials, true fiduciary duty, fee transparency, and six questions to avoid costly mistakes.

The data, which were presented at the AAN 2026 Annual Meeting, support the agents’ neurological safety, but longer follow-ups and dedicated outcome trials are needed to confirm these findings.

A tailored APPE rotation combines practice exposures and guided reflections, fostering professional identity formation and personal growth in pharmacy students.

Phase 3 SYMPHONY clinical trial data show reboxetine eases narcolepsy type 1 symptoms, improving functional impairment due to excessive daytime sleepiness (EDS) as well as mood symptoms.

A federal directive to expedite FDA review and expand research pathways for psychedelic therapies signals a potential shift in mental health treatment.

Lowering costs won’t improve health outcomes if the pharmacies dispensing those medications lack the authority, staffing, and infrastructure to function as clinical settings.

Oncology teams can address AI-driven cancer cures with empathy, evidence, and safer next steps to protect patients and trust.

Emerging data find buprenorphine in pregnancy matches methadone for autism and ADHD risk, supporting safer opioid MOUD access in pharmacy care.

FDA clears an oral TYK2 blocker for active psoriatic arthritis, delivering strong ACR20 gains with a familiar safety profile.

There is an increasing interest in de-escalation strategies for HER2-positive breast cancer aimed at decreasing toxicity exposure while maintaining efficacy.

EPCORE trials show epcoritamab plus lenalidomide and rituximab delivers responses in relapsed refractory follicular lymphoma with outpatient dosing.

Walgreens pilots hybrid pharmacists—4 days in-store, 1 day remote—seeking less burnout and more steady staffing.

McCreary and Dudley emphasize the role of pharmacists when optimizing antimicrobial use, supporting patient care across diverse settings, and driving education, research, and policy.

Pharmacists and students must stay up to date on vaccine recommendations amid changing guidelines.

Adjuvant PD-1/PD-L1 inhibitors improve disease-free and metastasis-free survival in patients with solid tumors but require careful patient selection.

Clinical trial insights link talquetamab resistance to GPRC5D loss in multiple myeloma; oncology pharmacy teams can spot escape and refine treatment.

When performed appropriately, medication reconciliations can reduce discrepancies from as high as 70% to as low as 15%.

COVID-19 infection may create lasting changes in the lung microenvironment—particularly through thymidine phosphorylase–driven pathways—that could increase the risk of lung cancer over time.